N/A N=34 Cell Phone Support to Promote Medication Adherence Among Adolescents and Young Adults With Chronic Illness
Medication Adherence
Primary: Self-Reported Medication Adherence — 86.55; 84.80; 68.75 percentage of 100
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=41 Adjunctive Mixed Salts Amphetamine for Depressed Adults With Incomplete Response to Current Antidepressant Therapy
Major Depressive Disorder
Primary: Change in Scores on the Massachusetts General Hospital Cognitive and Physical Functioning Questionnaire (MGH-CPFQ) — 27.5; 29; 22.6; 25 Scores on a scale
Phase 2 N=29 Study of Durvalumab (MEDI4736) (Anti-PD-L1) and Trametinib (MEKi) in MSS Metastatic Colon Cancer
Malignant Neoplasms of Digestive Organs · Colorectal Cancer · Colon Cancer
Primary: Immune-related Best Overall Response Rate. — 1 Participants
Phase 2 N=61 Ramucirumab in Treating Patients With Advanced or Metastatic, Previously Treated Biliary Cancers That Cannot Be Removed by Surgery
Cholangiocarcinoma · Liver and Intrahepatic Bile Duct Carcinoma · Stage III Gallbladder Cancer AJCC v7
Primary: Progression Free Survival of Ramucirumab in Advanced Biliary Cancers — 3.2 months
Phase 2 N=39 Study of PI3Kinase Inhibition (Copanlisib) and Anti-PD-1 Antibody Nivolumab in Relapsed/Refractory Solid Tumors With Expansions in Mismatch-repair Proficient (MSS) Colorectal Cancer
Unresectable or Metastatic Microsatellite Stable (MSS) Solid Tumor · Microsatellite Stable (MSS) Colon Cancer
Primary: Number of Participants Experiencing a Dose Limiting Toxicity — 0 Participants
N/A N=645 Assessment of an Investigational Frequent Replacement Silicone Hydrogel Lens
Refractive Ametropia
Primary: Distance Visual Acuity (VA) With Study Lenses - Completed Eyes — -0.05; -0.05; -0.05; -0.05 logMAR
N/A N=35 Hypofractionated Pre-operative Radiation Therapy for Soft Tissue Sarcomas of the Extremity and Chest-wall
Soft Tissue Sarcoma
Primary: Local Disease Control Assessed by Physical Examination — 0 Participants
N/A N=82 Comparing Surgical and Economical Parameters of Total Knee Replacement.
Osteo Arthritis Knee · Total Knee Arthroplasty
Primary: Compare Time-saving Associated With the Two Procedures. — 25.12; 28.47 minutes
N/A N=50 The First Puncture Success Rate of a Novel Injeq IQ-Tip™ System in Pediatric Lumbar Punctures
Lumbar Puncture
Primary: The First Puncture Success Rate — 79.5 percentage of procedures
Phase 3 N=1,511 20-valent Pneumococcal Conjugate Vaccine Safety Study in Healthy Infants
Pneumococcal Disease
Primary: Percentage of Participants With Local Reactions Within 7 Days After Dose 1 — 18.0; 16.5; 3.7; 3.0 Percentage of participants
Phase 3 N=200 Apathy in Dementia Methylphenidate Trial 2
Apathy · Alzheimer's Disease
Primary: Neuropsychiatric Inventory (NPI) — -4.5; -3.1 score on a scale
N/A N=69 Micropulse Laser Trabeculoplasty (MLT) Versus Selective Laser Trabeculoplasty (SLT) for Treatment of Open Angle Glaucoma
Open Angle Glaucoma
Primary: Intraocular Pressure Reduction — 17.01; 14.29 percentage change
Phase 2 N=120 COVID-19 Outpatient Pragmatic Platform Study (COPPS) - Acebilustat Sub-Protocol
Covid19
Primary: For Clinical Domain: Time-to-sustained-resolution — 26; NA days — p=0.07
Phase 2 N=60 A Study of ABT-263 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
Primary: Phase 1: Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and Discontinuations Due to Adverse Events (AEs) — 3; 6…
Phase 2 N=8 A Phase II Trial If Nivolumab, Lenalidomide and Dexamethasone in High Risk Smoldering Myeloma
Smoldering Multiple Myeloma
Primary: 2 Year Progression Free Percent — 62.5 percentage of participants